Expertise in
2
conditions

Akira Yamauchi

Kurashiki, JP 
Expertise in
2
conditions
Kurashiki, JP 
OverviewLocationsClinical Research

Overview

Akira Yamauchi practices in Kurashiki, Japan. Yamauchi is highly rated in 2 conditions, according to our data. Their top areas of expertise are Breast Cancer, Peripheral Neuropathy, Chronic Granulomatous Disease, Mastectomy, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 152 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Kurashiki, 7010192, Japan
Other Locations
Hirakata, Japan
Shizuoka, Japan
Nagoya, 4648601, Japan
Shimizu, 4240855, Japan
Okayama, Japan
Maebashi, 3718530, Japan
Osaka, Japan
Tochigi, Japan
Kitano, Japan
Nara-shi, Japan
Osaka, 5308480, Japan
Mibu, Japan
Otsu, Japan
Toyonaka, 5610825, Japan
Tokushima, Japan
Kita Gun, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus
A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: April 14, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)
A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

152 Total Publications

Comparison of the Anticancer Effects of a Complementary Peptide for Dickkopf WNT Signaling Pathway Inhibitor 3 (DKK3) With Conventional Anticancer Drugs in the Treatment of Oral Squamous Cell Carcinoma: A Pilot Study.
Comparison of the Anticancer Effects of a Complementary Peptide for Dickkopf WNT Signaling Pathway Inhibitor 3 (DKK3) With Conventional Anticancer Drugs in the Treatment of Oral Squamous Cell Carcinoma: A Pilot Study.
Journal: Cureus
Published: September 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yamauchi's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile